Business Context and Reporting Period
This Form 8-K Current Report was filed by Design Therapeutics, Inc. (DSGN) on August 18, 2021. The report discloses a material change in executive leadership regarding the appointment of a new Chief Accounting Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
The Board of Directors appointed Julie Burgess as Chief Accounting Officer and principal accounting officer, effective upon her commencement of employment (expected September 13, 2021). Upon this date, Dawn Giangiulio will cease serving as interim principal accounting officer but will retain her role as Controller.
Management Commentary and Compensation
Ms. Burgess brings over 25 years of experience in financial reporting and biopharmaceutical finance, including recent roles at Otonomy, Inc. and Apricus Biosciences, Inc. Her compensation package includes:
- Base Salary: $350,000 annually.
- Performance Bonus: Up to 35% of base salary. For the 2021 calendar year, the bonus is not prorated, and two-thirds of the opportunity is guaranteed.
- Equity: Stock option to purchase 135,000 shares of common stock. Vesting is 25% after 12 months, with the remainder vesting monthly over the subsequent 36 months.
The filing states there are no family relationships between Ms. Burgess and any director or executive officer, and no undisclosed arrangements exist.
Investor Verification Checklist
- Confirm the exact start date of Julie Burgess's employment to determine the precise effective date of the leadership transition.
- Review the specific corporate and individual objectives required to achieve the non-guaranteed portion of the 2021 performance bonus.
- Verify the grant date and exercise price of the 135,000 stock options in subsequent filings (e.g., Form 4 or 10-Q).
- Monitor future filings for any changes to the interim accounting structure following Ms. Giangiulio's transition.